Alzheimer’s treatment slows cognitive decline by a third, drug maker reports
Donanemab also reduced brain amyloid plaque levels, according to Eli Lilly.
Another experimental monoclonal antibody has shown promise in treating early Alzheimer’s disease, with Eli Lilly announcing its candidate can slow cognitive decline by a third compared with placebo.
The drug, donanemab, also led to significant reductions in brain amyloid plaque levels, based on amyloid PET imaging, the company said.
